ConductScience.org, home

Paper42394820

Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.

Wei XC and 3 others. Front Cell Infect Microbiol, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Papers, record 42394820. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42394820

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Exploratory model-based optimizing isavuconazole dosing regimens for Aspergillus spp. in adult patients according to serum albumin levels: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
PubMed
Journal
Front Cell Infect Microbiol
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-08-13
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Wei XCXiao-Chen
2Zhao MFMing-Feng
3Lyu HRHai-Rong
4Xiao XXia

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
PyridinesMajor topic
TriazolesMajor topic
Antifungal AgentsMajor topic
AspergillusMajor topic
AspergillosisMajor topic
Serum AlbuminMajor topic
NitrilesMajor topic
Humans
Monte Carlo Method
Microbial Sensitivity Tests
Adult
Hypoalbuminemia
Immunocompromised Host
Female
Middle Aged

Source PubMed

Download CSV of topics

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
140153171An Overview of Isavuconazole Clinical Use: A Multicentre Analysis of Indications, Exposure and Hepatic Safety.Clin Drug Investig2025https://conductscience.org/library/papers/40153171PubMed
225753636Pharmacodynamics of isavuconazole in an Aspergillus fumigatus mouse infection model.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/25753636PubMed
328803138Low Albumin Levels Are Associated with Mortality Risk in Hospitalized Patients.Am J Med2017https://conductscience.org/library/papers/28803138PubMed
426598096Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Pharmacotherapy2015https://conductscience.org/library/papers/26598096PubMed
535191210Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Isavuconazonium Sulfate in Healthy Adult Japanese Subjects.Clin Pharmacol Drug Dev2022https://conductscience.org/library/papers/35191210PubMed
625624327Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.Antimicrob Agents Chemother2015https://conductscience.org/library/papers/25624327PubMed
731119272Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy.J Antimicrob Chemother2019https://conductscience.org/library/papers/31119272PubMed
839540734Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial.Antimicrob Agents Chemother2024https://conductscience.org/library/papers/39540734PubMed
933782547High rate of invasive fungal infections after non-T cell depleted haploidentical allo-HSCT even under antifungal prophylaxis.Bone Marrow Transplant2021https://conductscience.org/library/papers/33782547PubMed
1040490059Population pharmacokinetics of isavuconazole in hematologic patients: implications for model-informed precision dosing.Eur J Pharm Sci2025https://conductscience.org/library/papers/40490059PubMed
1139138063A global perspective of the changing epidemiology of invasive fungal disease and real-world experience with the use of isavuconazole.Med Mycol2024https://conductscience.org/library/papers/39138063PubMed
1226000646Isavuconazole: a new extended spectrum triazole for invasive mold diseases.Future Microbiol2015https://conductscience.org/library/papers/26000646PubMed
1338436619Pharmacological management of invasive mold infections in solid organ transplant recipients.Expert Opin Pharmacother2024https://conductscience.org/library/papers/38436619PubMed
1428702763Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.Infection2017https://conductscience.org/library/papers/28702763PubMed
1532721598Evaluating posaconazole dosing regimens of the different formulations against Aspergillus spp. in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.Int J Antimicrob Agents2020https://conductscience.org/library/papers/32721598PubMed
1640240233Pharmacokinetic novelties of isavuconazole. Use in special situations.Rev Iberoam Micol2025https://conductscience.org/library/papers/40240233PubMed
1739200006Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.Antibiotics (Basel)2024https://conductscience.org/library/papers/39200006PubMed
1834188199Antifungal susceptibilities of opportunistic filamentous fungal pathogens from the Asia and Western Pacific Region: data from the SENTRY Antifungal Surveillance Program (2011-2019).J Antibiot (Tokyo)2021https://conductscience.org/library/papers/34188199PubMed
1936781411Population Pharmacokinetics, Exposure-Safety, and Probability of Target Attainment Analyses for Isavuconazole in Japanese Patients With Deep-Seated Mycoses.J Clin Pharmacol2023https://conductscience.org/library/papers/36781411PubMed
2040566598Optimization of Isavuconazole Dosing in Patients with Invasive Fungal Infections Through Therapeutic Drug Monitoring: Real-World Clinical Practice Experience.Life (Basel)2025https://conductscience.org/library/papers/40566598PubMed

See all 39 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42394820

GET https://conductscience.org/api/papers/v1/42394820/references?page=2